Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activation

The Canadian Cancer Trials Group is pleased to announce that HEC.1 (CALGB 80802) -- Phase III Intergroup Study of Sorafenib plus Doxorubicin versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma(HCC) -- was centrally activated 3 January 2011.

This is a first trial in HCC for the Canadian Cancer Trials Group and we are pleased to get this trial activated at this early stage (22/450 patients accrued to date overall).

Any questions about HEC.1 should be directed to the trial Study Coordinator, Eliot Frymire, at 613-533-6430 or